Enlivex LTD. (ENLV) — 6-K Filings

All 6-K filings from Enlivex LTD.. Browse 47 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (47)

Enlivex Ltd. Files Form 6-K with SEC — Apr 21, 2026 Risk: low
Enlivex Ltd. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release (EX-99.1) and other documents re
Enlivex Files Routine 6-K, Includes Press Release — Mar 26, 2026
Enlivex Ltd. filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing includes a current report and a press release, sugges
Enlivex Secures Financing via Convertible Note with Lind G — Mar 24, 2026
Enlivex Ltd. filed a 6-K on March 24, 2026, detailing a Securities Purchase Agreement dated March 23, 2026, with Lind G, which includes a Senior Secured Convert
6-K Filing — Dec 18, 2025
6-K Filing — Dec 4, 2025
Enlivex Therapeutics Closes Private Placement — Nov 26, 2025 Risk: medium
Enlivex Therapeutics Ltd. announced the closing of its previously reported private placement on November 24, 2025. The company, organized under the laws of Isra
6-K Filing — Nov 24, 2025
6-K Filing — Nov 18, 2025
Enlivex Therapeutics Files 6-K with Financials — Nov 14, 2025 Risk: low
Enlivex Therapeutics Ltd. filed a Form 6-K on November 14, 2025, reporting its unaudited condensed consolidated financial statements as of and for the period en
6-K Filing — Nov 10, 2025
Enlivex Therapeutics Ltd. Files 6-K Report — Sep 25, 2025 Risk: low
Enlivex Therapeutics Ltd. filed a Form 6-K on September 25, 2025, reporting on its activities as a foreign private issuer. The filing indicates the company's pr
Enlivex Therapeutics Ltd. CEO Letter to Shareholders — Sep 11, 2025 Risk: low
On September 11, 2025, Enlivex Therapeutics Ltd. issued a letter from its CEO to shareholders. The letter provided an update on the company's progress and strat
Enlivex Therapeutics Secures Israeli Patent for Cancer Drug — Sep 9, 2025 Risk: medium
Enlivex Therapeutics Ltd. announced on September 9, 2025, the issuance of an Israeli patent for its drug candidate, Allocetra. This patent covers the use of All
Enlivex Therapeutics Files 6-K Update — Aug 29, 2025 Risk: medium
Enlivex Therapeutics Ltd. filed a Form 6-K on August 29, 2025, reporting its financial statements for the period ending June 30, 2025. The company, formerly kno
Enlivex Therapeutics Reports Positive Phase 2b Data — Aug 18, 2025 Risk: medium
On August 18, 2025, Enlivex Therapeutics Ltd. announced three-month topline data from its Phase 2b clinical trial for Allocetra. The data showed a statistically
Enlivex Therapeutics to Host Webinar on August 18 — Aug 14, 2025 Risk: low
Enlivex Therapeutics Ltd. announced on August 14, 2025, that it will host a webinar on August 18, 2025, at 8:00 AM Eastern Time. The webinar will provide an upd
Enlivex Therapeutics Completes Phase II COVID-19 Trial Enrollment — Jul 28, 2025 Risk: medium
On July 28, 2025, Enlivex Therapeutics Ltd. announced that all 134 patients in the Phase II stage of its randomized, controlled trial for its drug Allocetra hav
Enlivex Therapeutics Files 6-K with Financials — May 30, 2025 Risk: low
Enlivex Therapeutics Ltd. filed a Form 6-K on May 30, 2025, reporting its unaudited condensed consolidated financial statements for the three-month periods ende
Enlivex Therapeutics to Present at OARSI 2025 World Congress — Apr 23, 2025 Risk: low
On April 23, 2025, Enlivex Therapeutics Ltd. announced it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2025 Wo
Enlivex Completes Patient Enrollment for Phase II COVID-19 Trial — Apr 21, 2025 Risk: medium
On April 21, 2025, Enlivex Therapeutics Ltd. announced the completion of patient enrollment for the Phase II stage of its randomized, controlled, blinded Phase
Enlivex Doses First Patient in Phase I Trial — Apr 3, 2025 Risk: medium
On April 3, 2025, Enlivex Therapeutics Ltd. announced that the first patient has been dosed in an investigator-initiated Phase I trial. This trial will evaluate
Enlivex Therapeutics Files 2024/2023 Financial Statements — Mar 31, 2025 Risk: low
Enlivex Therapeutics Ltd. filed a Form 6-K on March 31, 2025, reporting its audited consolidated financial statements for the years ended December 31, 2024, and
Enlivex Therapeutics Secures China Patent Allowance for Sepsis Treatment — Mar 17, 2025 Risk: medium
On March 17, 2025, Enlivex Therapeutics Ltd. announced that the China National Intellectual Property Administration issued a notice of allowance for a patent re
Enlivex Therapeutics to Discuss Phase I Trial Data — Mar 4, 2025 Risk: medium
On March 4, 2025, Enlivex Therapeutics Ltd. announced a webinar for investors scheduled for March 5, 2025, at 11:00 a.m. ET. The webinar will discuss positive i
Enlivex Therapeutics Reports Positive Phase II Trial Data — Mar 3, 2025 Risk: medium
On March 3, 2025, Enlivex Therapeutics Ltd. announced positive interim six-month efficacy data from the first stage of its Phase II Allocetra™ trial. The trial
Enlivex Therapeutics Addresses Fraudulent News — Feb 18, 2025 Risk: medium
On February 18, 2025, Enlivex Therapeutics Ltd. issued an urgent statement addressing fraudulent news circulating about the company. The company, formerly known
Enlivex Therapeutics gets Israeli MoH approval for Phase I sepsis trial — Dec 11, 2024 Risk: medium
On December 11, 2024, Enlivex Therapeutics Ltd. announced that the Israeli Ministry of Health has authorized the initiation of a Phase I investigator-initiated
Enlivex Therapeutics Reports Positive Phase I Data for Allocetra™ — Dec 3, 2024 Risk: medium
On December 3, 2024, Enlivex Therapeutics Ltd. announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II trial
Enlivex Therapeutics Files 6-K with Q3 Financials — Nov 29, 2024 Risk: low
Enlivex Therapeutics Ltd. filed a Form 6-K on November 29, 2024, reporting its unaudited condensed consolidated financial statements for the three and nine mont
Enlivex Therapeutics to Buy Up to $1M in Bitcoin — Nov 20, 2024 Risk: medium
On November 20, 2024, Enlivex Therapeutics Ltd. announced that its board of directors approved the purchase of up to $1 million in Bitcoin. This strategic move
Enlivex Doses First Patient in Phase I Solid Tumor Trial — Nov 14, 2024 Risk: medium
Enlivex Therapeutics Ltd. announced on November 14, 2024, the completion of dosing and initial follow-up for the first patient in its Phase I clinical trial. Th
Enlivex Therapeutics Enrolls First 10 Patients in Phase II Trial — Nov 12, 2024 Risk: medium
Enlivex Therapeutics Ltd. announced on November 12, 2024, the enrollment and dosing of the first 10 patients in the Phase II stage of its clinical trial for its
Enlivex Therapeutics Holds 2024 Annual Shareholder Meeting — Nov 8, 2024 Risk: low
Enlivex Therapeutics Ltd. held its 2024 Annual General Meeting of Shareholders on November 7, 2024. The company, organized under the laws of Israel, is headquar
Enlivex Therapeutics 2024 Shareholder Meeting Fails Due to Lack of Quorum — Oct 31, 2024 Risk: medium
Enlivex Therapeutics Ltd. held its 2024 Annual General Meeting of Shareholders on October 31, 2024. The meeting was convened but was not able to proceed due to
Enlivex Therapeutics Secures Japanese Patent Allowance — Oct 30, 2024 Risk: low
On October 30, 2024, Enlivex Therapeutics Ltd. announced that the Japanese Patent Office issued a notice of allowance for patent application number 2022-512861.
Enlivex Therapeutics Gets Green Light for Phase II COVID-19 Trial — Sep 26, 2024 Risk: medium
On September 26, 2024, Enlivex Therapeutics Ltd. announced that the Danish Medicines Agency has authorized the initiation of the Phase II stage of its clinical
Enlivex Therapeutics Trial Continues After Positive DSMB Review — Sep 24, 2024 Risk: medium
On September 24, 2024, Enlivex Therapeutics Ltd. announced that the independent Data and Safety Monitoring Board (DSMB) completed an interim data review for its
Enlivex Therapeutics Files September 2024 6-K Report — Sep 11, 2024 Risk: low
Enlivex Therapeutics Ltd. filed a Form 6-K on September 11, 2024, reporting on its activities for the month of September 2024. The filing is a report of a forei
Enlivex Therapeutics Files 6-K with Financials — Aug 30, 2024 Risk: medium
Enlivex Therapeutics Ltd. filed a Form 6-K on August 30, 2024, reporting its unaudited condensed consolidated financial statements for the period ending June 30
Enlivex Therapeutics Gets Green Light for Phase I Trial — Jul 23, 2024 Risk: medium
On July 23, 2024, Enlivex Therapeutics Ltd. announced that the Israeli Ministry of Health has authorized the initiation of a Phase I clinical trial for their dr
Enlivex Doses First Patient in COVID-19 Trial — Jun 24, 2024 Risk: medium
On June 24, 2024, Enlivex Therapeutics Ltd. announced that the first patient has been dosed in an investigator-initiated, randomized, placebo-controlled Phase I
Enlivex Therapeutics to Host Investor Webinar — Jun 20, 2024 Risk: low
Enlivex Therapeutics Ltd. announced on June 20, 2024, that it will host an investor webinar on June 25, 2024, at 4:15 p.m. ET. The webinar will provide an updat
Enlivex Therapeutics Reports Positive Phase I/II Trial Data — Jun 17, 2024 Risk: medium
On June 17, 2024, Enlivex Therapeutics Ltd. announced positive interim data from a Phase I/II investigator-initiated clinical trial for its drug candidate, Allo
Enlivex Therapeutics Files 6-K with Financial Updates — Jun 14, 2024 Risk: low
Enlivex Therapeutics Ltd. filed a Form 6-K on June 14, 2024, reporting its unaudited condensed consolidated financial statements for the three-month periods end
Enlivex Therapeutics Gets Green Light for COVID-19 Trial — Jun 3, 2024 Risk: medium
On June 3, 2024, Enlivex Therapeutics Ltd. announced it received regulatory authorization to begin an investigator-initiated, randomized clinical trial for its
Enlivex Therapeutics Enters Securities Purchase Agreement — May 29, 2024 Risk: medium
On May 27, 2024, Enlivex Therapeutics Ltd. entered into a securities purchase agreement with a single investor. The company, incorporated in Israel, is a pharma
Enlivex Therapeutics Secures $5M Private Placement — May 28, 2024 Risk: medium
On May 28, 2024, Enlivex Therapeutics Ltd. announced a definitive agreement with a single healthcare-focused institutional investor for a private placement. The

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX